Chinese Aflibercept Market
Dublin, Aug. 10, 2022 (GLOBE NEWSWIRE) — The “Chinese Aflibercept Market Survey Report 2022-2031” report has been added to from ResearchAndMarkets.com offer.
Aflibercept is an anti-VEGF drug, primarily used to treat neovascular age-related macular degeneration (AMD) and other retinopathies caused by visual impairment. Aflibercept was jointly developed by Regeneron and Bayer. Regeneron holds exclusive sales rights in the US market, while Bayer obtains exclusive sales rights outside the US. Their Aflibercept, EYLEA, was launched in China in 2018. As of July 2022, Bayer AG is the sole manufacturer in the Chinese market of Aflibercept.
According to this market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY 8.3 million in 2018 to CNY 238 million in 2021. The annual growth rate in 2021 was 116% which slowed down due to the covid19 outbreak. The CAGR of sales value of aflibercept in China is 206% from 2018 to 2021.
The analyst analyzes that as the epidemic situation has improved and hospitals resume their operations, the sales of Aflibercept will experience recovery growth from 2023 to 2026. In addition, the sales will also increase due to the market expansion. Currently, China has only approved two indications for Aflibercept, including the treatment of AMD and the treatment of DME.
However, Aflibercept had five indications approved worldwide, which means that sales will continue to grow as the number of indications increases. On the other hand, although the anti-VEGF ophthalmic drug market to which Aflibercept belongs accounts for the largest market share in the ophthalmic drug industry, the penetration rate of the anti-VEGF drug is still low.
The penetration rate of the anti-VEGF drug is around 1% in China, while it exceeds 5% in the United States. Market demand has not yet reached saturation, sales will continue to increase. In addition, Aflibercept was included in the national health insurance catalog at the beginning of 2020, so the price was lowered, which reduces the burden on patients and will boost sales in the future.
Qilu Pharmaceutical, a local Chinese pharmaceutical company, received CDE (CENTER FOR DRUG EVALUATION, NMPA) approval for its marketing authorization application for aflibercept intravitreal injection in April 2022, which is the first biosimilar application for aflibercept in China.
According to this market research, a number of other pharmaceutical companies in China are in the process of generating aflibercept, such as Clover Biopharmaceuticals’ aflibercept intraocular injection, which is in the clinical phase of application, and Shandong Boan Biotechnology Co.
The generic version of aflibercept is expected to enter the Chinese market within the next five years, but it is unlikely to have a significant impact on Bayer’s original drug in the short term.
The impact of COVID-19 on the Chinese aflibercept market
China Aflibercept Sales Value and Volume 2016-2020
Competitive Landscape of Chinese Aflibercept Market
aflibercept price in china
Aflibercept Price in China by Regions and Manufacturers
Analysis of factors affecting the development of the Chinese aflibercept market
China Aflibercept Market Outlook 2021 to 2025
Main topics covered:
1 Relevant concepts of Aflibercept
1.1 Indications for Aflibercept
1.2 Development of Aflibercept in China
1.3 Government Approval of Aflibercept in China
1.4 The impact of COVID-19 on Aflibercept sales in China
2 Aflibercept Sales in China, 2018-2021
2.1 Commercial value of Aflibercept
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Aflibercept Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Aflibercept Sales by Dosage Form in China, 2018-2021
2.3.1 Intraocular injection
2.3.2 Analysis of other dosage forms
3 Analysis of Aflibercept Key Manufacturers in China, 2018-2021
3.1 Aflibercept Major Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Bayer AG
3.2.1 Company profile
3.2.2 EYLEA (Bayer’s Aflibercept) Sales in China
4 Aflibercept Price for Different Manufacturers in China, 2021-2022
4.1 Bayer AG (EYLEA)
5 China Aflibercept Drugs Market Outlook, 2022- 2031
5.1 Influencing Factors of China Aflibercept Market Development
5.1.1 The impact of COVID-19 on the Chinese Aflibercept market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
For more information on this report, visit https://www.researchandmarkets.com/r/fpm0ji
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900